Semaglutide is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Common Adverse Effects According to clinical trial data, gastrointestinal effects are most frequently reported: nausea, vomiting, diarrhea, constipation, and abdominal discomfort
Whilst mild redness, swelling, or tenderness lasting a few hours is normal, symptoms persisting beyond 48 hours, spreading redness suggesting infection (cellulitis), increasing pain, warmth, or pus discharge require assessment
If you feel your current dose is insufficient, dose escalation within the approved range (up to 15 mg weekly) is the standard clinical approach
In general, semaglutide isnt recommended for patients with moderate-to-severe gastroparesis